Alltracel Healthcare Services (AHS), the newly created division of AIM listed Alltracel Pharmaceuticals has located at NovaUCD. Pictured are Dr Keith Real, Chief Scientific Officer, Alltracel Pharmaceuticals; Conor Walshe, CEO, AHS and Dr Pat Frain, Director, NovaUCD
Alltracel Healthcare Services (AHS), the newly created division of AIM listed Alltracel Pharmaceuticals has located to NovaUCD. NovaUCD is the Innovation and Technology Transfer Centre at University College Dublin.
AHS has been established to provide scientific research, clinical trial and development services for all of Alltracel’s business units, subsidiaries and relevant partnerships. AHS also offers its services to outside companies in the pharmaceutical, medical and healthcare technologies sectors who are seeking an external step-up in speed of innovation, technology development and commercialisation.
Commenting on the establishment of AHS and its location at NovaUCD, Dr Keith Real, Chief Scientific Officer, Alltracel said, “We have always had a great working relationship with UCD in particular with the Conway Institute so we are very pleased to be able to base Alltracel Healthcare Services in NovaUCD. NovaUCD is a centre for innovation and technology which sits well with Alltracel’s corporate vision.”
Welcoming AHS to NovaUCD Dr Pat Frain, Director, NovaUCD said, “We are delighted that Alltracel Pharmaceuticals which already has strong research links with UCD and with a proven record in innovation has decided to base its new division at NovaUCD.” He added, “The strategic importance of this relationship is clear since AHS will be offering multinational companies an outsourced partner that will facilitate and co-ordinate their R&D requirements in a flexible and timely way.”
